NBI-827104
Phase 2Terminated 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Epileptic Encephalopathy
Conditions
Epileptic Encephalopathy, Continuous Spike and Wave During Sleep
Trial Timeline
Jun 7, 2022 → Jan 27, 2025
NCT ID
NCT05301894About NBI-827104
NBI-827104 is a phase 2 stage product being developed by Neurocrine Biosciences for Epileptic Encephalopathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT05301894. Target conditions include Epileptic Encephalopathy, Continuous Spike and Wave During Sleep.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05301894 | Phase 2 | Terminated |
Competing Products
14 competing products in Epileptic Encephalopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Perampanel Oral Suspension + Perampanel Tablet | Eisai | Phase 2 | 52 |
| Lorazepam | Pfizer | Phase 3 | 76 |
| Lorazepam | Pfizer | Pre-clinical | 22 |
| levetiracetam (add-on) | UCB | Phase 2 | 49 |
| ESES treated with clobazam | Lundbeck | Pre-clinical | 20 |
| NBI-921352 + Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| NBI-921352 | Neurocrine Biosciences | Phase 2 | 49 |
| NBI-827104 + Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| Epidiolex 100 mg/mL Oral Solution | Jazz Pharmaceuticals | Phase 1 | 30 |
| 1.0mg/kg/day PRAX-562 + 1.5mg/kg/day PRAX-562 + Placebo | Praxis Precision Medicines | Phase 3 | 74 |
| 1mg elsunersen + 0.5mg elsunersen | Praxis Precision Medicines | Phase 3 | 74 |
| SAGE-547 | Supernus Pharmaceuticals | Pre-clinical | 18 |
| SAGE-547 | Supernus Pharmaceuticals | Phase 1/2 | 36 |
| SAGE-547 + Placebo | Supernus Pharmaceuticals | Phase 3 | 72 |